{"id":"NCT01141283","sponsor":"Purdue Pharma LP","briefTitle":"Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase","officialTitle":"Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Mod to Sev OA Pain of Hip or Knee: A 6-Month Open-label Extension Phase","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-04","primaryCompletion":"2004-07","completion":"2004-07","firstPosted":"2010-06-10","resultsPosted":"2010-09-21","lastUpdate":"2012-09-03"},"enrollment":290,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis"],"interventions":[{"type":"DRUG","name":"Buprenorphine transdermal patch","otherNames":[]},{"type":"DRUG","name":"Buprenorphine transdermal patch","otherNames":[]},{"type":"DRUG","name":"Buprenorphine transdermal patch","otherNames":[]}],"arms":[{"label":"BTDS","type":"EXPERIMENTAL"}],"summary":"The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).","primaryOutcome":{"measure":"The Number of Participants With Adverse Events as a Measure of Safety and Tolerability","timeFrame":"6 months.","effectByArm":[{"arm":"Extension Phase (BTDS 5, 10, or 20)","deltaMin":0,"sd":0}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":42,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":290},"commonTop":["Headache","Application site rash","Application site erythema","Nausea","Constipation"]}}